SANGAMO THERAPEUTICS, INC. (SGMOQ) Net margin 2016–2025
SANGAMO THERAPEUTICS, INC. (SGMOQ) net profit margin by fiscal year — reported net income divided by reported revenue.
-310.8%FY2025 · since FY2016: -369.6% → -310.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -310.8% | -141.4 pp |
| FY2024 | -169.4% | -23.1 pp |
| FY2023 | -146.3% | +26.5 pp |
| FY2022 | -172.8% | -11.7 pp |
| FY2021 | -161.1% | -58.7 pp |
| FY2020 | -102.4% | -9.4 pp |
| FY2019 | -92.9% | -12.0 pp |
| FY2018 | -80.9% | +68.3 pp |
| FY2017 | -149.2% | +220.4 pp |
| FY2016 | -369.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SGMOQ financial trends
SGMOQ RevenueSGMOQ Net incomeSGMOQ Gross profitSGMOQ Gross marginSGMOQ Operating incomeSGMOQ Operating marginSGMOQ Operating cash flowSGMOQ Free cash flowSGMOQ Capital expendituresSGMOQ Return on equitySGMOQ Stock buybacksSGMOQ Dividends paidSGMOQ Total assetsSGMOQ Total liabilitiesSGMOQ Shareholders’ equitySGMOQ overview →